FEFaruk Ekinci

Faruk Ekinci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Faruk Ekinci has a total of 261 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Platelet Transfusion Practices in the PICUs: Multicenter, Observational Study, in Türkiye and Northern Cyprus, 2024

    by Çağlar Ödek, Fevzi Aydoğdu, Didar Arslan, Gökhan Ocakoğlu, Alper Oğlakçioğlu, Sadik Kaya, Büşra Daştan İnce, Emrah Gün, Ayşe Aşik, Muhterem Duyu, et al.

    Objectives: We aimed to describe the use of platelet transfusions among critically ill children managed in Türkiye in late 2024. Secondarily, we sought to determine these practices in relation to the 2022 Transfusion and Anemia Expertise Initiative-Control/Avoidance of Bleeding (TAXI-CAB) recommendations for critically ill pediatric patients. Design: Prospective study (October–December 2024). Setting: 22 PICUs in Türkiye and Northern Cyprus. Patients: Patients of 1 month to 18 years who received at least one platelet transfusion in the PICU. Interventions: None Measurement and Main Results: Out of 2693 PICU admissions, 200 patients (7.4%) received 577 platelet transfusions. Of the transfusions, 383 of 577 transfusions (66.4%) were for prophylaxis, most frequently for isolated thrombocytopenia (194/383, 50.7%). Regarding the transfusion threshold for prophylaxis, in the 194 cases of isolated thrombocytopenia, the median (interquartile range [IQR]) pretransfusion platelet count was 24 (IQR, 16–38) × 10 9 /L, which differed from the TAXI-CAB consensus statement guidance of less than 10 × 10 9 /L. Platelet transfusion, as opposed to not, was associated with 20-fold greater odds of 28-day mortality ( p < 0.001), and among the 200 patients receiving platelets, multivariable analysis showed that lower pretransfusion platelet count, support with invasive mechanical ventilation, and hospital-acquired infections collectively accounted for 34% of the variance in model performance for classifying 28-day mortality. Conclusions: Our 2024 national, multicenter PICU study across Türkiye and Northern Cyprus shows that around two-thirds of transfusion episodes were for prophylaxis, and multivariable logistic regression modeling identified patient factors associated with greater odds of 28-day mortality. The median pretransfusion threshold for isolated thrombocytopenia was around 20 × 10 9 /L, which is double the less than 10 × 10 9 /L in the 2022 TAXI-CAB consensus statement. Given the heterogeneity of critically ill patients and practice environments, understanding the reasons behind these practices may help inform future research and consensus recommendations.

  • Open Access

    Impact of Immunotherapy Combinations on Clinical Outcomes in Children with Acute Flaccid Paralysis: A Multicenter Intensive Care Study

    by Edin Botan, Merve Boyraz, Servet Yüce, Hazal Ceren Tuğrul, Emrah Gün, Şeyma Erdem Torun, Hasan Özen, Merve Havan, Ayşe Aşık, Anar Gurbanov, et al.

    Objective: Acute flaccid paralysis (AFP) is a syndrome characterized by the rapid onset of limb weakness and decreased muscle tone, frequently accompanied by respiratory or bulbar involvement. Methods: This retrospective multicenter study evaluated the clinical characteristics, treatment modalities, intensive care processes, and outcomes of 68 children diagnosed with AFP who were admitted to pediatric intensive care units (PICUs) between January 1, 2018, and January 1, 2023. Results: The patients’ ages ranged from 1 month to 18 years (mean 7.9 ± 4.5 years), and 33 (48.5%) were male. The mean PICU stay was 15.4 ± 19.5 days, and the mean total hospital stay was 23.3 ± 21.1 days. Respiratory support was required in 42 patients (61.8%). All patients received intravenous immunoglobulin (IVIG). Therapeutic plasma exchange (TPE) was administered to 25 of 43 Guillain–Barré syndrome (GBS) patients, 7 of 11 transverse myelitis (TM) patients, and 11 of 14 acute disseminated encephalomyelitis (ADEM) patients. Among 14 intubated GBS patients, 5 received IVIG for ≤2 days and 9 for ≥4 days. The duration of invasive mechanical ventilation (MV) was significantly longer in patients receiving IVIG for ≥4 days (P=.044). Guillain–Barré syndrome patients treated with combined IVIG and TPE had longer PICU stays compared with those receiving IVIG alone (P=.001). Conclusion: Combination immunotherapies were associated with longer MV duration and PICU stay compared with monotherapy in AFP patients. In intubated GBS patients, administration of IVIG over 2 days was associated with a shorter duration of invasive MV.

  • Open Access

    Multiple organ dysfunction syndrome in pediatric colchicine poisoning: a national cohort study from Türkiye

    by Faruk Eki̇nCi̇, Di̇nÇer Yildizdaş, Ozden Özgür Horoz, Hayri̇ Levent Yilmaz, Sevcan Bi̇lEn, İlKer Ünal, İkBal Türker, Esra Şevketoğlu, Ni̇hAl Akçay, Agop Çitak, et al.

    Background/aim: Colchicine poisoning has been associated with systemic toxicity, multiple organ dysfunction syndrome (MODS), and mortality. In the present study, the demographic, clinical, and laboratory characteristics of pediatric colchicine poisoning cases and the incidence of organ failure are investigated to identify potential risk factors associated with MODS. Materials and methods: Included in this retrospective multicenter cohort study were pediatric patients admitted to 28 tertiary-care pediatric intensive care units with a diagnosis of colchicine poisoning. Demographic data, clinical and laboratory findings, and clinical outcomes were extracted from medical records. MODS was defined as dysfunction involving at least two organ systems. Multivariable logistic regression analysis was performed to identify the variables independently associated with MODS. Results: Of the 150 patients included in the study, 40% were younger than 5 years and 52% were older than 13 years. Gastrointestinal symptoms were most prominent, with nausea and vomiting observed in 64.7%, abdominal pain in 36.7%, and diarrhea in 24%. Overall, 66% developed no organ failure, while single-organ failure occurred in 7.3% and 26.7% developed MODS. The coagulation system was most frequently affected (26%), followed by the hematological (19.3%) and immunological (18%) systems. Multivariable logistic regression analysis identified the baseline PRISM III score, ingested colchicine dose per kilogram of body weight, and initial sodium, creatinine, and aspartate aminotransferase (AST) levels as independent predictors of MODS. Conclusion: MODS can develop at ingestion doses lower than 0.5 mg/kg, which have historically been considered safe. Higher ingested doses and elevated PRISM III scores were associated with MODS, although these findings are derived from retrospective observational data and should not be interpreted as causal or as direct clinical recommendations. Further prospective studies are needed to clarify relevant doses, interventions, and prognostic factors in pediatric colchicine poisoning associated with MODS.

  • Open Access

    A Soluble Guanylate Cyclase Stimulator (Riociguat) Poisoning in Children: A Case Report

    by Hasan Ali Telefon, İkBal Turker, Faruk Ekinci, Ozden Ozgur Horoz, Dincer Yildizdas

  • Ventilator-Associated Pneumonia in Pediatric Intensive Care: 7-Year Evaluation

    by Asena Ünal, Fatma Kılınç, Fatma Tuğba Çetin, Özlem Özgür Gündeşlioğlu, Ümmühan Çay, Derya Alabaz, Filiz Kibar, Özden Özgür Horoz, Faruk Ekinci, Dinçer Yıldızdaş

  • Çocuk Yoğun Bakımda Ventilatör İlişkili Pnömoni: 7 Yıllık Değerlendirme

    by Asena Ünal, Fatma Kılınç, Fatma Tuğba Çetin, Özlem Özgür Gündeşlioğlu, Ümmühan Çay, Derya Alabaz, Filiz Kibar, Özden Özgür Horoz, Faruk Ekinci, Dinçer Yıldızdaş

  • Open Access

    An Assessment of Intermittent and Continuous Enteral Feeding in Critically Ill Children

    by Merve Misirlioglu, Dincer Yildizdas, Faruk Ekinci, Nihal Akcay, Ilyas Bingol, Ebru Sahin, Fatih Varol, Muhterem Duyu, Ayse Asik, Fatih Durak, et al.

    Background: The inability to ensure adequate nutrition for patients, and failure to provide adequate calorie and protein intake, result in malnutrition, leading to increased morbidity and mortality. The present study assesses the two approaches to enteral nutrition—intermittent and continuous enteral feeding—in critically ill pediatric patients in Türkiye to determine the superiority of one method over the other. Methods: Included in this multicenter prospective study were patients receiving enteral nutrition via a tube who were followed up over a 3-month period. Anthropometric data, calorie and protein intake, and signs of feeding intolerance were evaluated in a comparison of the different feeding methods. Results: A total of 510 patients were examined. In the continuous enteral feeding (CEF) group, 20.2% of patients developed metabolic abnormalities, and 49.5% experienced enteral nutrition intolerance, both of which were higher than in the intermittent enteral feeding (IEF) group, and the differences were statistically significant. No significant differences were observed between the two feeding methods in terms of reaching the target calorie intake on days 2 and 7 (p > 0.05). On day 7, there were significant differences between the two feeding methods in terms of calorie and protein intake (p = 0.023 and 0.014, respectively). Conclusions: In the present study, assessing the IEF and CEF approaches to enteral nutrition, critically ill pediatric patients receiving intermittent feeding exhibited lower rates of enteral nutrition intolerance and metabolic abnormalities. Furthermore, the calorie and protein intake on day 7 were noted to be higher in the IEF group than in the CEF group. Further randomized controlled trials are needed to confirm the findings of the present study.


  • Clinical experience with ceftazidime/avibactam for the treatment of extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in neonates and children

    by Ozlem Ozgur Gundeslioglu, Zeliha Haytoglu, Hatice Hale Gumus, Faruk Ekinci, Filiz Kibar, Ummuhan Cay, Derya Alabaz, Ferda Ozlu, Ozden Ozgur Horoz, Rıza Dincer Yıldızdas

    Purpose Klebsiella pneumoniae is a significant cause of healthcare-associated infections, resulting in high morbidity and mortality rates due to limited treatment options. In this study, we aimed to evaluate the treatment outcomes and the safety of Ceftazidime-avibactam in infections caused by extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in pediatric patients. Methods This study included pediatric patients who received ceftazidime-avibactam treatment due to extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae infections, monitored in the pediatric intensive care, neonatal intensive care, and pediatric wards of Cukurova University Faculty of Medicine between 2022 and 2023. Patients' microbiological responses, clinical responses, medication side effects, and 30-day survival rates were evaluated. Results Eleven pediatric patients were included in the study, of whom nine were male (81.8%). The median age at the initiation of ceftazidime-avibactam treatment was 15 months (range: 14 days—183 months). Sepsis was diagnosed in 9 patients (81.8%). Two premature infants (27 and 35 weeks) were admitted to the neonatal ICU. Regarding the Klebsiella pneumoniae strains, 10 (91%) were extensively drug-resistant (XDR), and 1 (9%) was pandrug-resistant (PDR). Eight strains (72.7%) were carbapenem-resistant, and 9 (81.8%) were colistin-resistant. Microbiological response was noted in 8 patients (72.7%), clinical response was evident in 6 patients (54.5%). The 30-day survival rate was 54.5%, with six patients surviving. Conclusion In our study, ceftazidime-avibactam has been identified as a significant treatment option for resistant Klebsiella pneumoniae infection in critically ill children and premature infants with sepsis and organ failure, and it has been found to be well tolerated.


  • Therapeutic plasma exchange in critically ill children: 18-year experience of a tertiary care paediatric intensive care unit

    by Faruk Ekinci, Dincer Yildizdas, Ozden Ozgur Horoz, Ahmet Yontem, Ibrahim Halil Acar, Meltem Karadamar, Birol Guvenc


  • Acute Dystonia Due to Pregabalin Abuse in an Adolescent

    by Ezgi Çay, İkBal Türker, Faruk Eki̇nci̇, Sevcan Bi̇len, Ozden Ozgur Horoz, Hayri Yılmaz, Dinçer Yıldızdaş

    Pregabalin is a drug used to treat neuropathic pain, epilepsy, and fibromyalgia. However, the number of reported cases of pregabalin abuse is steadily growing. This case showed dystonia, an effect not previously documented as a consequence of pregabalin administration. A 16-year-old male patient with no known pre-existing medical conditions was admitted to the pediatric emergency department for the first time, complaining of drowsiness caused by pregabalin abuse. During the patient's follow-up, dystonia was observed, and biperiden was administered at a repeating dose. Subsequently, he was moved to the pediatric intensive care unit (PICU) for further tests and treatment. After three days of follow-up, the patient was discharged due to the absence of complaints. This case report presents dystonia resulting from pregabalin abuse, a condition that has not previously been documented in the literature.